A Study Comparing BL-B01D1 With Chemotherapy of Physician ' s Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer

Conditions: HR+HER2- Breast Cancer Interventions: Drug: BL-B01D1; Drug: Eribulin; Drug: Vinorelbine; Drug: Gemcitabine; Drug: Capecitabine Sponsors: Sichuan Baili Pharmaceutical Co., Ltd.; Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials